137 related articles for article (PubMed ID: 16490624)
1. Adherence to guidelines for ESRD anemia management.
Hynes DM; Stroupe KT; Kaufman JS; Reda DJ; Peterman A; Browning MM; Huo Z; Sorbara D
Am J Kidney Dis; 2006 Mar; 47(3):455-61. PubMed ID: 16490624
[TBL] [Abstract][Full Text] [Related]
2. Comparing VA and private sector healthcare costs for end-stage renal disease.
Hynes DM; Stroupe KT; Fischer MJ; Reda DJ; Manning W; Browning MM; Huo Z; Saban K; Kaufman JS;
Med Care; 2012 Feb; 50(2):161-70. PubMed ID: 21945972
[TBL] [Abstract][Full Text] [Related]
3. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis.
Moist LM; Muirhead N; Wazny LD; Gallo KL; Heidenheim AP; House AA
Ann Pharmacother; 2006 Feb; 40(2):198-203. PubMed ID: 16449549
[TBL] [Abstract][Full Text] [Related]
5. [Is the management of anemia in hemodialysis patients improving in France? Results of the DiaNE study].
Kessler M; Landais P; Canivet E; Yver L; Bataille P; Brillet G; Commenges B; Koné S
Nephrol Ther; 2009 Apr; 5(2):114-21. PubMed ID: 19042175
[TBL] [Abstract][Full Text] [Related]
6. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
Wiecek A; Covic A; Locatelli F; Macdougall IC;
Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
[TBL] [Abstract][Full Text] [Related]
7. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
Lacson E; Ofsthun N; Lazarus JM
Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
[TBL] [Abstract][Full Text] [Related]
8. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
9. Once-every-2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients.
Mircescu G; Gârneată L; Ciocâlteu A; Golea O; Gherman-Căprioară M; Capsa D; Mota E; Gusbeth-Tatomir P; Ghenu A; Bălută S; Constantinovici N; Covic AC
Am J Kidney Dis; 2006 Sep; 48(3):445-55. PubMed ID: 16931218
[TBL] [Abstract][Full Text] [Related]
10. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
11. Past, present, and future of chronic kidney disease anemia management in the United States.
Wish JB
Adv Chronic Kidney Dis; 2009 Mar; 16(2):101-8. PubMed ID: 19233069
[TBL] [Abstract][Full Text] [Related]
12. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
13. Methods for estimating and comparing VA outpatient drug benefits with the private sector.
Render ML; Nowak J; Hammond EK; Roselle G
Med Care; 2003 Jun; 41(6 Suppl):II61-9. PubMed ID: 12773828
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
16. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
Leslie DL; Rosenheck RA
J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
[TBL] [Abstract][Full Text] [Related]
17. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
Thitiarchakul S; Tasanarong A
J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients.
Besarab A; Reyes CM; Hornberger J
Am J Kidney Dis; 2002 Sep; 40(3):439-46. PubMed ID: 12200793
[TBL] [Abstract][Full Text] [Related]
19. [Spanish survey on anaemia management].
Pérez García R
Nefrologia; 2003; 23(4):300-11. PubMed ID: 14558329
[TBL] [Abstract][Full Text] [Related]
20. What would VA nursing home care cost? Methods for estimating private sector payments.
Hendricks A; Whitford J; Nugent G
Med Care; 2003 Jun; 41(6 Suppl):II52-60. PubMed ID: 12773827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
